A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Local Institution - 0003, San Pedro Alcántara, Málaga

Local Institution - 0004, Torino

Local Institution - 0018, Milan

Local Institution - 0017, Bergamo

Local Institution - 0009, Cartagena

Local Institution - 0034, Atlanta

Local Institution - 0012, Padua

Local Institution - 0027, Cantabria

Local Institution - 0006, Seville

Local Institution - 0032, Edgewood

Local Institution - 0035, Meldola

Local Institution - 0026, Napoli

Local Institution - 0028, Albuquerque

Local Institution - 0036, Issaquah

Local Institution - 0030, Seattle

Local Institution - 0005, Concepción

Local Institution - 0015, Las Condes

Local Institution - 0007, Anchorage

Local Institution - 0013, Phoenix

Local Institution - 0010, San Francisco

Local Institution - 0037, Edmonds

Local Institution - 0019, Thessaloniki

Local Institution - 0014, Athens

Local Institution - 0029, Marousi

Local Institution - 0023, Holargos, Athens

Local Institution - 0008, Piraeus

Local Institution - 0033, Thessaloniki

Local Institution - 0021, Roma

Local Institution - 0011, Barcelona

Local Institution - 0022, Barcelona

Local Institution - 0020, Badalona